BioSpace News Archive

Shares of Insys plunged more than 25 percent in trading Wednesday after the company said in a filing with the U.S. Securities and Exchange Commission that it could soon run out of revenue and may have to resort to liquidating its assets.

In the wake of the scandal caused by a Chinese researcher’s use of CRISPR-Cas9 gene editing to alter the DNA of embryos for seven couples, leading scientists called for a moratorium on heritable genome editing.

Francis’ last day with Sandoz will be March 31. Francesco Balestrieri, who is currently Region Head Europe for Sandoz, has been appointed interim CEO. He will report to Vas Narasimhan, the CEO of Novartis

On day two of Cowen and Company’s 39th Annual Health Care Conference, more companies shared insight into pipeline development. BioSpace rounded up a few of the stories.

Intranasal betahistine program progressing towards proof-of-concept studies in acute vertigo (AM-125) and antipsychotic-induced weight gain (AM-201)

GENFIT S.A. announced its intention to issue and sell, subject to market and other conditions, 5,000,000 of its ordinary shares in a global offering to specified categories of investors, comprised of an initial public offering of American Depositary Shares, each representing one ordinary share, in the United States, and a concurrent private placement of ordinary shares in Europe and other countries outside of the US.

The study tracked more than 250 veterans in over 600 visits at the Richard L. Roudebush VA Medical Center in Indianapolis, attempting to identify a molecule in the blood to track stress intensity. Over a decade, they evaluated gene expression in participants in both low- and high-stress states.

New York City, despite its size, population and access to venture capital and top academic institutions, is not a major center for life science startups. But recent reports suggest that may—at least a little bit—be changing.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, has been shortlisted for the German Digital Health Award 2019.